# A Multimodal Integrated System For Improved Cardiopulmonary Resuscitation

> **NIH NIH R44** · CPR THERAPEUTICS, INC. · 2022 · $597,368

## Abstract

Abstract
CPR Therapeutics Inc. is developing the first multimodal automated system for cardiopulmonary
resuscitation (CPR). This technology integrates and synchronizes multiple pump-mechanisms with enhanced
defibrillation, and will be the first device to improve outcomes of patients in cardiac arrest with a number-needed-
to-treat predictive of commercial success. It will do this while enhancing patient and provider safety. Nationally,
approximately 650,000 individuals suffer cardiac arrest each year. Fifty years after the description of CPR,
survival is generally below 10%, and a significant fraction of resuscitated patients are left with neurologic
impairment. Remarkably, the standard-of-care remains manual chest compressions performed by rescuers with
their hands. It has been estimated that the societal costs related to out-of-hospital cardiac arrest alone may be
in excess of $33 billion a year in the US. Without question, clinically effective improvements in CPR are among
the greatest unmet medical needs. All previous attempts at effective CPR devices have: 1) focused on only one
enhancement at a time, 2) had disappointing outcomes in randomized trials, 3) cause skeletal injuries in most
patients, and 4) provide no benefit over manual CPR. In a series of pilot studies, CPR Therapeutics demonstrated
that combinations of cardiac output- and venous return-enhancing techniques may offer additive or even
synergistic benefits to hemodynamics. As envisioned, the Company’s multifunctional system is based on the
concept that multiple CPR pump mechanisms, combined with synchronization of defibrillation and pulseless
electrical activity (PEA) CPR, will synergize both the hemodynamics and electrophysiology. These approach
should significantly improve real-world clinical outcomes. In this Direct-to-Phase II project, CPR Therapeutics
will: 1) Design and build a 3rd generation porcine test-bed capable of high-fidelity millisecond control of the
multimodal CPR pump-mechanisms, 2) Optimize the system configuration and component designs in a porcine
model of ventricular fibrillation, and 3) Design and build a human clinical prototype under a design-control and
Quality Management System (QMS). This device will be subjected to structural and functional bench testing in
anticipation of filing for an FDA IDE. In addition to the development of the technology, the project’s scope-of-
work will add significantly to our basic science knowledge of the interactions between CPR pump-mechanisms
and patient-component synchronizations.

## Key facts

- **NIH application ID:** 10546620
- **Project number:** 1R44HL164199-01A1
- **Recipient organization:** CPR THERAPEUTICS, INC.
- **Principal Investigator:** HENRY R HALPERIN
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $597,368
- **Award type:** 1
- **Project period:** 2022-09-15 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10546620

## Citation

> US National Institutes of Health, RePORTER application 10546620, A Multimodal Integrated System For Improved Cardiopulmonary Resuscitation (1R44HL164199-01A1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10546620. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*